EP2300825A4 - P/gf-1-begleitdiagnostikverfahren und -produkte - Google Patents

P/gf-1-begleitdiagnostikverfahren und -produkte

Info

Publication number: EP2300825A4
Authority: EP; European Patent Office
Prior art keywords: products; diagnostic methods; companion diagnostic; companion; methods
Prior art date: 2008-06-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP09767690A

Other languages

English (en)

French (fr)

Other versions

EP2300825A1 (de

Inventor

Saul Datwyler

David J Hawksworth

Don M Laird

Dominick L Pucci

David C Sogin

Joan D Tyner

Robert N Ziemann

Richard R Lesniewski

Evelyn Mary Mckeegan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-18

Filing date

2009-06-17

Publication date

2012-04-25

2009-06-16 Priority claimed from US12/485,114 external-priority patent/US8741287B2/en

2009-06-17 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2011-03-30 Publication of EP2300825A1 publication Critical patent/EP2300825A1/de

2012-04-25 Publication of EP2300825A4 publication Critical patent/EP2300825A4/de

Status Withdrawn legal-status Critical Current

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP09767690A 2008-06-18 2009-06-17 P/gf-1-begleitdiagnostikverfahren und -produkte Withdrawn EP2300825A4 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US7362408P	2008-06-18	2008-06-18
US8917208P	2008-08-15	2008-08-15
US11006308P	2008-10-31	2008-10-31
US12/485,114 US8741287B2 (en)	2008-06-18	2009-06-16	PlGF-1 assay and kits and components thereof
PCT/US2009/047714 WO2009155381A1 (en)	2008-06-18	2009-06-17	P/gf-1 companion diagnostic methods and products

Publications (2)

Publication Number	Publication Date
EP2300825A1 EP2300825A1 (de)	2011-03-30
EP2300825A4 true EP2300825A4 (de)	2012-04-25

Family

ID=41434433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP09767690A Withdrawn EP2300825A4 (de)	2008-06-18	2009-06-17	P/gf-1-begleitdiagnostikverfahren und -produkte

Country Status (6)

Country	Link
EP (1)	EP2300825A4 (de)
JP (1)	JP2011525241A (de)
CN (1)	CN102224419A (de)
CA (1)	CA2728449A1 (de)
MX (1)	MX2010014228A (de)
WO (1)	WO2009155381A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1163254B1 (de)	1999-02-26	2008-01-30	The University of British Columbia	Antisense-therapie für trpm-2
US7569551B2 (en)	2000-02-25	2009-08-04	The University Of British Columbia	Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
JP5917416B2 (ja) *	2010-03-05	2016-05-11	オプフトハルモプハルマエージー	栄養補助チョコレート又はコンパウンドチョコレート製品
CN113683705A (zh)	2011-07-01	2021-11-23	恩格姆生物制药公司	用于代谢病症和疾病治疗的组合物、应用和方法
UY34812A (es) *	2012-05-18	2013-12-31	Teva Pharma	Método para el tratamiento del cáncer de pulmón de células no pequeñas
NZ630484A (en)	2012-11-28	2017-04-28	Ngm Biopharmaceuticals Inc	Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en)	2012-11-28	2016-03-22	Ngm Biopharmaceuticals, Inc.	Compositions comprising variants and fusions of FGF19 polypeptides
WO2014105939A1 (en)	2012-12-27	2014-07-03	Ngm Biopharmaceuticals, Inc.	Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en)	2012-12-27	2016-03-01	Ngm Biopharmaceuticals, Inc.	Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015183890A2 (en)	2014-05-28	2015-12-03	Ngm Biopharmaceuticals, Inc.	Methods and compositions for the treatment of metabolic disorders and diseases
CA2951153A1 (en)	2014-06-16	2015-12-23	Ngm Biopharmaceuticals, Inc.	Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh)	2014-10-23	2022-03-04	恩格姆生物制药公司	包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en)	2014-11-07	2016-05-12	Ngm Biopharmaceuticals, Inc.	Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
AU2016353988B2 (en)	2015-11-09	2019-09-26	Ngm Biopharmaceuticals, Inc.	Methods for treatment of bile acid-related disorders
TWI746505B (zh) *	2016-01-25	2021-11-21	法商賽諾菲公司	通過測量血漿生物標記的水平預測疑似患有癌症的患者使用阿柏西普的治療的結果的方法
AU2017315459B2 (en)	2016-08-26	2023-06-29	Ngm Biopharmaceuticals, Inc.	Methods of treating fibroblast growth factor 19-mediated cancers and tumors
GB2616177A (en) *	2020-11-10	2023-08-30	Ningbo Aucheer Biotechnology Co Ltd	Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070037224A1 (en) *	2005-08-11	2007-02-15	Hamer Peter J	Quantitative assays for PDGFR-beta in body fluids
US20070254295A1 (en) *	2006-03-17	2007-11-01	Prometheus Laboratories Inc.	Methods of predicting and monitoring tyrosine kinase inhibitor therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030049262A1 (en) *	1998-10-02	2003-03-13	Susan Love	Methods for identification, diagnosis, and treatment of breast cancer
US7435419B2 (en) *	2002-07-19	2008-10-14	Beth Israel Deaconess Medical Center	Methods of diagnosing and treating pre-eclampsia or eclampsia
US7767792B2 (en) *	2004-02-20	2010-08-03	Ludwig Institute For Cancer Research Ltd.	Antibodies to EGF receptor epitope peptides
DE102005022047A1 (de) *	2005-05-09	2006-11-30	Dade Behring Marburg Gmbh	Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
CN101534865A (zh) *	2005-10-19	2009-09-16	Ibc药品公司	生物活性装配体的制备方法及其用途
WO2007056011A2 (en) *	2005-11-02	2007-05-18	Bayer Healthcare Llc	Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CN101517078A (zh) *	2006-05-31	2009-08-26	貝丝以色列女执事医疗中心	诊断和治疗妊娠并发症的方法
US20080071151A1 (en) *	2006-06-30	2008-03-20	Sogin David C	Method and Apparatus for Diagnosing Pre-eclampsia
JP2010509289A (ja) *	2006-11-09	2010-03-25	アボットゲーエムベーハーウントコンパニーカーゲー	チロシンキナーゼ阻害剤の経口投与用薬学的剤形

2009
- 2009-06-17 EP EP09767690A patent/EP2300825A4/de not_active Withdrawn
- 2009-06-17 MX MX2010014228A patent/MX2010014228A/es not_active Application Discontinuation
- 2009-06-17 CA CA2728449A patent/CA2728449A1/en not_active Abandoned
- 2009-06-17 WO PCT/US2009/047714 patent/WO2009155381A1/en active Application Filing
- 2009-06-17 JP JP2011514788A patent/JP2011525241A/ja active Pending
- 2009-06-17 CN CN2009801321990A patent/CN102224419A/zh active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070037224A1 (en) *	2005-08-11	2007-02-15	Hamer Peter J	Quantitative assays for PDGFR-beta in body fluids
US20070254295A1 (en) *	2006-03-17	2007-11-01	Prometheus Laboratories Inc.	Methods of predicting and monitoring tyrosine kinase inhibitor therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBERT D H ET AL: "Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 5, no. 4, 1 April 2006 (2006-04-01), pages 995 - 1006, XP002403181, ISSN: 1535-7163 *
CHIUNG-NIEN CHEN ET AL: "The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer", CANCER LETTERS, vol. 213, no. 1, 1 September 2004 (2004-09-01), pages 73 - 82, XP055020729, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2004.05.020 *
EBOS JOHN M L ET AL: "Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 43, 23 October 2007 (2007-10-23), pages 17069 - 17074, XP055020654, ISSN: 0027-8424 *
See also references of WO2009155381A1 *
SOO ET AL: "The effect of varying doses of ABT-869 on biomarkers of angiogensis and their correlation with pharmacodynamic outcome", no. Abst. 14535, May 2008 (2008-05-01), pages 1 - 2, XP002670638, Retrieved from the Internet <URL:http://tinyurl.com/847l6aq> [retrieved on 20120229] *

Also Published As

Publication number	Publication date
WO2009155381A1 (en)	2009-12-23
CN102224419A (zh)	2011-10-19
CA2728449A1 (en)	2009-12-23
JP2011525241A (ja)	2011-09-15
MX2010014228A (es)	2011-03-29
EP2300825A1 (de)	2011-03-30

Publication	Publication Date	Title
EP2300825A4 (de)	2012-04-25	P/gf-1-begleitdiagnostikverfahren und -produkte
HK1171792A1 (zh)	2013-04-05	診斷裝置和相關方法
GB0800144D0 (en)	2008-02-13	Electrocardiographic device and method
GB0813709D0 (en)	2008-09-03	Method and product
EP2419872A4 (de)	2013-01-30	Messung von gemütszuständen und deren ausdruck im tonfall
EP2299904A4 (de)	2012-09-26	Medizinische diagnostische vorrichtungen und verfahren
EP2633278A4 (de)	2014-05-28	Photoakustischer sensor
ZA201104742B (en)	2012-02-29	Strains and methods for improving ruminant health and/or performance
GB0819720D0 (en)	2008-12-03	Methods and products
GB0921001D0 (en)	2010-01-13	Products and uses
EP2578153A4 (de)	2014-09-03	Audiometer und verfahren dafür
EP2545375A4 (de)	2013-10-30	Analytsensor und entsprechende verfahren
GB0819883D0 (en)	2008-12-03	Product and uses
GB0918392D0 (en)	2009-12-02	Diagnostic and therapeutic methods
GB0821250D0 (en)	2008-12-31	Displacement measurement arrangement and method
HK1161720A1 (en)	2012-08-03	Dihydroetorphines and their preparation
PL2245463T3 (pl)	2014-06-30	Sposób diagnozowania
EP2350001A4 (de)	2011-11-16	Neue benzylidene-indolinonen und ihre medische und diagnostische verwendung
GB0905076D0 (en)	2009-05-06	Diagnostic kits and methods
GB0802162D0 (en)	2008-03-12	Disposable products
GB0814657D0 (en)	2008-09-17	Compsoitions and methods for maintaining lipid health
GB0903348D0 (en)	2009-04-08	Compounds and methods relating thereto
GB0816772D0 (en)	2008-10-22	Medical product
GB0803731D0 (en)	2008-04-09	Methods and products
AU2008906072A0 (en)	2008-12-11	Diagnostic and monitoring methods and products

Legal Events

Date	Code	Title	Description
2011-02-25	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-03-30	17P	Request for examination filed	Effective date: 20110117
2011-03-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
2011-03-30	AX	Request for extension of the european patent	Extension state: AL BA RS
2011-06-22	RIN1	Information on inventor provided before grant (corrected)	Inventor name: PUCCI, DOMINICK, L. Inventor name: MCKEEGAN, EVELYN, MARY Inventor name: ZIEMANN, ROBERT, N. Inventor name: TYNER, JOAN, D. Inventor name: SOGIN, DAVID, C. Inventor name: HAWKSWORTH, DAVID, J. Inventor name: DATWYLER, SAUL Inventor name: LAIRD, DON, M. Inventor name: LESNIEWSKI, RICHARD, R.
2011-09-21	DAX	Request for extension of the european patent (deleted)
2012-04-18	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/74 20060101ALI20120313BHEP Ipc: G01N 33/574 20060101AFI20120313BHEP Ipc: C07K 16/22 20060101ALI20120313BHEP
2012-04-25	A4	Supplementary search report drawn up and despatched	Effective date: 20120327
2012-04-25	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/574 20060101AFI20120320BHEP Ipc: C07K 16/22 20060101ALI20120320BHEP Ipc: G01N 33/74 20060101ALI20120320BHEP
2012-05-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1155804 Country of ref document: HK
2013-01-16	17Q	First examination report despatched	Effective date: 20121218
2014-07-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2014-08-20	18D	Application deemed to be withdrawn	Effective date: 20140226
2018-01-12	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1155804 Country of ref document: HK